Julian Jude

2.6k total citations
20 papers, 1.0k citations indexed

About

Julian Jude is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Julian Jude has authored 20 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 5 papers in Hematology and 4 papers in Oncology. Recurrent topics in Julian Jude's work include Protein Degradation and Inhibitors (6 papers), Acute Myeloid Leukemia Research (5 papers) and CRISPR and Genetic Engineering (5 papers). Julian Jude is often cited by papers focused on Protein Degradation and Inhibitors (6 papers), Acute Myeloid Leukemia Research (5 papers) and CRISPR and Genetic Engineering (5 papers). Julian Jude collaborates with scholars based in Austria, United States and Netherlands. Julian Jude's co-authors include Johannes Zuber, Tobias Neumann, Matthias Samwer, Daniel W. Gerlich, Philipp S. Schmalhorst, Thomas Hoffmann, Christian Umkehrer, Jesse Lipp, D. I. Jones and Nullin Divecha and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Julian Jude

19 papers receiving 1.0k citations

Peers

Countries citing papers authored by Julian Jude

Since Specialization

Citations

This map shows the geographic impact of Julian Jude's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julian Jude with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julian Jude more than expected).

Fields of papers citing papers by Julian Jude

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julian Jude. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julian Jude. The network helps show where Julian Jude may publish in the future.

Co-authorship network of co-authors of Julian Jude

This figure shows the co-authorship network connecting the top 25 collaborators of Julian Jude. A scholar is included among the top collaborators of Julian Jude based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julian Jude. Julian Jude is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CRISPR GENome and epigenome engineering improves loss-of-function genetic-screening approaches 2025 ·Cell Reports Methods ·(unknown), Chiara Bernardini, (unknown), (unknown), (unknown), (unknown), Zeynab Najafova, Steven A. Johnsen, Stefan Legewie, Franziska R. Traube, Julian Jude, Philipp Rathert	0
2	SPOP targets the immune transcription factor IRF1 for proteasomal degradation 2023 ·eLife ·(unknown), Milica Vunjak, (unknown), (unknown), (unknown), (unknown), Matthias Hinterndorfer, Melanie de Almeida, (unknown), Jingkui Wang, (unknown), Julian Jude, Thomas Decker, Johannes Zuber, Gijs A. Versteeg	4
3	EVI1 drives leukemogenesis through aberrant ERG activation 2022 ·Blood ·Johannes Schmoellerl, Inês Amorim Monteiro Barbosa, Martina Minnich, (unknown), Leonie Smeenk, Marije Havermans, Thomas Eder, Tobias Neumann, Julian Jude, Michaela Fellner, Anja Ebert, (unknown), Ruud Delwel, Florian Grebien, Johannes Zuber	19
4	DNA sequence and chromatin modifiers cooperate to confer epigenetic bistability at imprinting control regions 2022 ·Nature Genetics ·Stefan Butz, Nina Schmolka, Ino D. Karemaker, Rodrigo Villaseñor, (unknown), Silvia Domcke, Esther C. H. Uijttewaal, Julian Jude, Florian Lienert, Arnaud Krebs, (unknown), Xue Bao, Johannes Zuber, Ulrich Elling, Dirk Schübeler, Tuncay Baubec	16
5	Comprehensive CRISPR-Cas9 screen identifies factors which are important for plasmablast development 2022 ·Frontiers in Immunology ·(unknown), Maria Fischer, Markus Schäfer, Michaela Fellner, Julian Jude, Johannes Zuber, Meinrad Busslinger, Miriam Wöhner	3
6	S117: EVI1 DRIVES LEUKEMOGENESIS THROUGH ABERRANT ERG ACTIVATION 2022 ·HemaSphere ·Johannes Schmoellerl, Inês Amorim Monteiro Barbosa, Martina Minnich, (unknown), Leonie Smeenk, Marije Havermans, Thomas Eder, Tobias Neumann, Julian Jude, Michaela Fellner, Anja Ebert, (unknown), Ruud Delwel, Florian Grebien, Johannes Zuber	1
7	AKIRIN2 controls the nuclear import of proteasomes in vertebrates 2021 ·Nature ·Melanie de Almeida, Matthias Hinterndorfer, Hanna L. Brunner, Irina Grishkovskaya, (unknown), Alexander Schleiffer, Julian Jude, Sumit Deswal, (unknown), Milica Vunjak, Thomas Lendl, Richard Imre, Elisabeth Roitinger, Tobias Neumann, (unknown), Michael Schutzbier, Karl Mechtler, Gijs A. Versteeg, David Haselbach, Johannes Zuber	64
8	Parallel PRC2/cPRC1 and vPRC1 pathways silence lineage-specific genes and maintain self-renewal in mouse embryonic stem cells 2020 ·Science Advances ·(unknown), Carina Pribitzer, Jingkui Wang, (unknown), (unknown), Qing Zhao, Thomas R. Burkard, Brian Reichholf, Suhn K. Rhie, Julian Jude, (unknown), Johannes Zuber, Oliver Bell	39
9	Multilayered VBC score predicts sgRNAs that efficiently generate loss-of-function alleles 2020 ·Nature Methods ·Georg Michlits, Julian Jude, Matthias Hinterndorfer, Melanie de Almeida, Gintautas Vainorius, Maria Hubmann, Tobias Neumann, Alexander Schleiffer, Thomas R. Burkard, Michaela Fellner, (unknown), (unknown), Johannes Zuber, Ulrich Elling	85
10	STAG1 vulnerabilities for exploiting cohesin synthetic lethality in STAG2-deficient cancers 2020 ·Life Science Alliance ·Petra van der Lelij, J.A. Newman, Simone Lieb, Julian Jude, V.L. Katis, Thomas Hoffmann, Matthias Hinterndorfer, Gerd Bader, Norbert Kraut, Mark Pearson, Jan‐Michael Peters, Johannes Zuber, O. Gileadi, Mark Petronczki	24
11	Isolating live cell clones from barcoded populations using CRISPRa-inducible reporters 2020 ·Nature Biotechnology ·Christian Umkehrer, (unknown), (unknown), Julian Jude, (unknown), Tobias Neumann, (unknown), Lisa Haas, Jesse Lipp, Thomas R. Burkard, Michaela Fellner, Thomas Wiesner, Johannes Zuber, Anna C. Obenauf	61
12	SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis 2018 ·Science ·Matthias Muhar, Anja Ebert, Tobias Neumann, Christian Umkehrer, Julian Jude, Corinna Wieshofer, Philipp Rescheneder, Jesse Lipp, Veronika A. Herzog, Brian Reichholf, David A. Cisneros, Thomas Hoffmann, Moritz F. Schlapansky, Pooja Bhat, Arndt von Haeseler, Thomas Köcher, Anna C. Obenauf, Johannes Popow, Stefan L. Ameres, Johannes Zuber	237
13	MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity 2018 ·Nature Communications ·Anna Skucha, (unknown), (unknown), Mareike Roth, Thomas Eder, Adrián César‐Razquin, Alexey Stukalov, Sarah Vittori, Matthias Muhar, Bin Lü, Martin Aichinger, Julian Jude, André C. Müller, Balázs Győrffy, Christopher R. Vakoc, Peter Valent, Keiryn L. Bennett, Johannes Zuber, Giulio Superti‐Furga, Florian Grebien	43
14	A vital sugar code for ricin toxicity 2017 ·Cell Research ·Jasmin Taubenschmid, Johannes Stadlmann, (unknown), Tove Irene Klokk, Cory D. Rillahan, Andreas Leibbrandt, Karl Mechtler, James C. Paulson, Julian Jude, Johannes Zuber, Kirsten Sandvig, Ulrich Elling, Thorsten Marquardt, Christian Thiel, Christian Koerner, Josef Penninger	20
15	DNA Cross-Bridging Shapes a Single Nucleus from a Set of Mitotic Chromosomes 2017 ·Cell ·Matthias Samwer, (unknown), (unknown), Philipp S. Schmalhorst, Julian Jude, Johannes Zuber, Daniel W. Gerlich	155
16	Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts 2017 ·eLife ·Petra van der Lelij, Simone Lieb, Julian Jude, Gordana Wutz, (unknown), Katrina J. Falkenberg, Andreas Schlattl, Jozef Ban, Raphaela Schwentner, Thomas Hoffmann, Heinrich Kovar, Francisco X. Real, Todd Waldman, Mark Pearson, Norbert Kraut, Jan‐Michael Peters, Johannes Zuber, Mark Petronczki	79
17	PIP4K and the role of nuclear phosphoinositides in tumour suppression 2015 ·Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids ·Roberta Fiume, (unknown), Zahid H. Shah, Willem‐Jan Keune, D. I. Jones, Julian Jude, Nullin Divecha	45
18	PAX5 loss imposes a reversible differentiation block in b-progenitor acute lymphoblastic leukemia 2014 ·Experimental Hematology ·Grace Liu, Luisa Cimmino, Julian Jude, Yifang Hu, Mutlu Kartal, Matthew T. Witkowski, Mark McKenzie, Sarah A. Best, Laura Tuohey, Charles G. Mullighan, Michael A. Farrar, Stephen L. Nutt, Gordon K. Smyth, Johannes Zuber, Ross A. Dickins	3
19	A targeted knockdown screen of genes coding for phosphoinositide modulators identifies PIP4K2A as required for acute myeloid leukemia cell proliferation and survival 2014 ·Oncogene ·Julian Jude, Gary J. Spencer, Xu Huang, Tim D.D. Somerville, D. I. Jones, Nullin Divecha, Tim C. P. Somervaille	67
20	Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia 2014 ·Genes & Development ·(unknown), Luisa Cimmino, Julian Jude, Yifang Hu, Matthew T. Witkowski, Mark McKenzie, Mutlu Kartal‐Kaess, Sarah A. Best, Laura Tuohey, Yang Liao, Wei Shi, Charles G. Mullighan, Michael A. Farrar, Stephen L. Nutt, Gordon K. Smyth, Johannes Zuber, Ross A. Dickins	65

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact